

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 23, 2026

PE Mouse Anti-TCF-7/TCF-1 Antibody

RRID:AB_2687845

Type: Antibody

Proper Citation

BD Biosciences Cat# 564217, RRID:AB_2687845

Antibody Information

URL: http://antibodyregistry.org/AB_2687845

Proper Citation: BD Biosciences Cat# 564217, RRID:AB_2687845

Target Antigen: TCF-7/TCF-1

Host Organism: mouse

Clonality: monoclonal

Comments: Intracellular staining (flow Cytotoxicityometry)

Antibody Name: PE Mouse Anti-TCF-7/TCF-1 Antibody

Description: This monoclonal targets TCF-7/TCF-1

Target Organism: mouse, human

Clone ID: S33-966

Antibody ID: AB_2687845

Vendor: BD Biosciences

Catalog Number: 564217

Record Creation Time: 20250819T231716+0000

Record Last Update: 20250820T045220+0000

Ratings and Alerts

No rating or validation information has been found for PE Mouse Anti-TCF-7/TCF-1 Antibody.

No alerts have been found for PE Mouse Anti-TCF-7/TCF-1 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 64 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Gracia G, et al. (2026) Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy. Cancer immunology research, 14(3), 450.

Pang J, et al. (2026) Law-NQO1 redox boosts the pentose phosphate pathway to confer stem-like properties and antitumor durability in effector CD8+ T cells. Cell chemical biology, 33(3), 321.

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. Cancer research communications, 6(7), 1619.

Denk D, et al. (2025) IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis. Immunity, 58(3), 701.

Shimba A, et al. (2025) Stress-induced glucocorticoids enhance acute inflammation by promoting the differentiation of Th17 cells. Cell reports, 44(8), 116093.

Corgnac S, et al. (2025) TGF- β and IL-12 conversely orchestrate the formation of CD103+ CD8 tumor-resident memory T cells to regulate response to therapeutic cancer vaccine. iScience, 28(8), 113147.

Huang L, et al. (2025) Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer. Cell reports. Medicine, 6(8), 102251.

Zhang P, et al. (2025) Eomesodermin+ CD4+ T cells are critical for curative immunotherapy outcomes. Immunity, 58(12), 3024.

Rubio RM, et al. (2025) The transcription factor Helios restrains the anti-tumor capacity of CD8+ T cells. Cell reports, 44(12), 116680.

Izzati FN, et al. (2025) Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans. Cell reports, 44(7), 115933.

Earnshaw CH, et al. (2025) Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGF β Axis. Cancer discovery, OF1.

Humblin E, et al. (2025) The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+CD8+ T cells. *Immunity*, 58(8), 1966.

Dai Z, et al. (2025) Single-cell analysis of temporal immune cell dynamics in alopecia areata reveals a causal role for clonally expanded CD8+ T cells in disease. *Cell reports*, 44(7), 115798.

Rotta G, et al. (2025) Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein. *Journal for immunotherapy of cancer*, 13(5).

Ngiow SF, et al. (2024) LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. *Cell*, 187(16), 4336.

Yu J, et al. (2024) Progesterone-driven B7-H4 contributes to onco-fetal immune tolerance. *Cell*, 187(17), 4713.

Abadie K, et al. (2024) Reversible, tunable epigenetic silencing of TCF1 generates flexibility in the T cell memory decision. *Immunity*, 57(2), 271.

Memon D, et al. (2024) Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. *Cancer cell*, 42(2), 209.

Jaeger-Ruckstuhl CA, et al. (2024) Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. *Immunity*, 57(2), 287.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. *Cell reports*, 43(2), 113712.